|
WO2013088457A1
|
|
Genetic variants useful for risk assessment of thyroid cancer
|
|
WO2013080227A1
|
|
Genetic variants useful for risk assessment of arterial disease
|
|
WO2013061342A1
|
|
Variants conferring risk of intracranial aneurysm and abdominal aortic aneurysm
|
|
WO2013065072A1
|
|
Risk variants of prostate cancer
|
|
WO2013035114A1
|
|
Tp53 genetic variants predictive of cancer
|
|
WO2012172575A1
|
|
Genetic variants for predicting risk of breast cancer
|
|
WO2012123972A1
|
|
Genetic variants useful for risk assessment of thyroid cancer
|
|
WO2012117424A1
|
|
Brip1 variants associated with risk for cancer
|
|
EP2673383A1
|
|
Variants predictive of risk of gout
|
|
EP2663656A1
|
|
Genetic variants as markers for use in urinary bladder cancer risk assessment
|
|
WO2012085948A1
|
|
Genetic variants useful for risk assessment of thyroid cancer
|
|
EP2640857A1
|
|
Genetic risk factors of sick sinus syndrome
|
|
WO2012029080A1
|
|
Sequence variants associated with prostate specific antigen levels
|
|
WO2011161700A1
|
|
Genetic markers for risk management of vascular disease
|
|
WO2011104731A1
|
|
Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment
|
|
WO2011104730A1
|
|
Genetic variants predictive of lung cancer risk
|
|
WO2011095999A1
|
|
Genetic variants for predicting risk of breast cancer
|
|
WO2011042920A1
|
|
Genetic variants indicative of vascular conditions
|
|
WO2011011598A1
|
|
Process for preparing 4- { (s) -2- (4-(4-chlorophenoxy) phenoxymethyl) pyrrolidin-1-yl) } butyric acid and salts thereof
|
|
EP2451977A1
|
|
Genetic markers associated with risk of diabetes mellitus
|
